246 related articles for article (PubMed ID: 22718320)
41. Identification and quantification of dopamine receptor 2 in human eutopic and ectopic endometrium: a novel molecular target for endometriosis therapy.
Novella-Maestre E; Carda C; Ruiz-Sauri A; Garcia-Velasco JA; Simon C; Pellicer A
Biol Reprod; 2010 Nov; 83(5):866-73. PubMed ID: 20574053
[TBL] [Abstract][Full Text] [Related]
42. [New medical treatments for painful endometriosis: CNGOF-HAS Endometriosis Guidelines].
Legendre G; Delbos L; Hudon E; Chabbert-Buffet N; Geoffron S; Sauvan M; Fernandez H; Bouet PE; Descamps P
Gynecol Obstet Fertil Senol; 2018 Mar; 46(3):256-263. PubMed ID: 29530558
[TBL] [Abstract][Full Text] [Related]
43. FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470).
Chen GJ; Weylie B; Hu C; Zhu J; Forough R
J Cell Biochem; 2007 Aug; 101(6):1492-504. PubMed ID: 17295210
[TBL] [Abstract][Full Text] [Related]
44. Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane.
Nap AW; Dunselman GA; Griffioen AW; Mayo KH; Evers JL; Groothuis PG
Fertil Steril; 2005 Mar; 83(3):793-5. PubMed ID: 15749522
[TBL] [Abstract][Full Text] [Related]
45. Challenges in the development of novel therapeutic strategies for treatment of endometriosis.
Vanhie A; Tomassetti C; Peeraer K; Meuleman C; D'Hooghe T
Expert Opin Ther Targets; 2016; 20(5):593-600. PubMed ID: 26558646
[TBL] [Abstract][Full Text] [Related]
46. Endometriosis and angiogenesis.
May K; Becker CM
Minerva Ginecol; 2008 Jun; 60(3):245-54. PubMed ID: 18547987
[TBL] [Abstract][Full Text] [Related]
47. Anti-angiogenic treatment of endometriosis: biochemical aspects.
Taylor RN; Mueller MD
Gynecol Obstet Invest; 2004; 57(1):54-6. PubMed ID: 14974461
[No Abstract] [Full Text] [Related]
48. Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors.
Lefkove B; Govindarajan B; Arbiser JL
Expert Rev Anti Infect Ther; 2007 Aug; 5(4):573-9. PubMed ID: 17678422
[TBL] [Abstract][Full Text] [Related]
49. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Yildiz C; Kacan T; Akkar OB; Karakus S; Kacan SB; Ozer H; Cetin A
Reprod Sci; 2015 Nov; 22(11):1445-51. PubMed ID: 25963915
[TBL] [Abstract][Full Text] [Related]
50. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis.
Laschke MW; Menger MD
Hum Reprod Update; 2007; 13(4):331-42. PubMed ID: 17347159
[TBL] [Abstract][Full Text] [Related]
51. [Studies on endocrine therapy of endometriosis].
Terakawa N
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Aug; 41(8):981-9; discussion 1000-7. PubMed ID: 2530291
[TBL] [Abstract][Full Text] [Related]
52. The role of GnRH analogues in endometriosis-associated apoptosis and angiogenesis.
Tesone M; Bilotas M; Barañao RI; Meresman G
Gynecol Obstet Invest; 2008; 66 Suppl 1():10-8. PubMed ID: 18936547
[TBL] [Abstract][Full Text] [Related]
53. Medical treatment of endometriosis.
Garcia-Velasco JA; Quea G
Minerva Ginecol; 2005 Jun; 57(3):249-55. PubMed ID: 16166934
[TBL] [Abstract][Full Text] [Related]
54. Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo.
Laschke MW; Schwender C; Scheuer C; Vollmar B; Menger MD
Hum Reprod; 2008 Oct; 23(10):2308-18. PubMed ID: 18603648
[TBL] [Abstract][Full Text] [Related]
55. Prodrug of green tea epigallocatechin-3-gallate (Pro-EGCG) as a potent anti-angiogenesis agent for endometriosis in mice.
Wang CC; Xu H; Man GC; Zhang T; Chu KO; Chu CY; Cheng JT; Li G; He YX; Qin L; Lau TS; Kwong J; Chan TH
Angiogenesis; 2013 Jan; 16(1):59-69. PubMed ID: 22948799
[TBL] [Abstract][Full Text] [Related]
56. The effects of sunitinib on endometriosis.
Pala HG; Erbas O; Pala EE; Artunc Ulkumen B; Akman L; Akman T; Oltulu F; Yavasoglu A
J Obstet Gynaecol; 2015 Feb; 35(2):183-7. PubMed ID: 25093747
[TBL] [Abstract][Full Text] [Related]
57. Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model.
Ercan CM; Kayaalp O; Cengiz M; Keskin U; Yumusak N; Aydogan U; Ide T; Ergun A
Arch Gynecol Obstet; 2015 May; 291(5):1103-11. PubMed ID: 25367601
[TBL] [Abstract][Full Text] [Related]
58. The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions.
Bourlev V; Volkov N; Pavlovitch S; Lets N; Larsson A; Olovsson M
Reproduction; 2006 Sep; 132(3):501-9. PubMed ID: 16940291
[TBL] [Abstract][Full Text] [Related]
59. Pharmacologic management of endometriosis.
Saltiel E; Garabedian-Ruffalo SM
Clin Pharm; 1991 Jul; 10(7):518-31. PubMed ID: 1830521
[TBL] [Abstract][Full Text] [Related]
60. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions.
Laschke MW; Elitzsch A; Vollmar B; Vajkoczy P; Menger MD
Hum Reprod; 2006 Jan; 21(1):262-8. PubMed ID: 16172144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
